The role of Zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report.

Abstract

Correlation between dietary intake and occurrence of prostate cancer has gained significant support in recent years. Although a direct correlation has yet to be proven between inflammation and prostate cancer, chronic or recurrent inflammation has been hypothesized to be the major predisposing factor for this disease. The authors have been studying Zyflamend, a novel herbal anti-inflammatory mixture, as a potential chemopreventive agent in a phase 1 trial for patients diagnosed with prostatic intraepithelial neoplasia. They report the results of the first patient who has completed the 18-month study in which 24 patients were assigned to a cohort and placed on successive herbal supplement regimen starting with Zyflamend alone.

• Authors: Samuil Rafailov, Sam Cammack, Brian A Stone, Aaron E Katz
• Journal: Integrative cancer therapies (Integr Cancer Ther) Vol. 6 Issue 1 Pg. 74-6 (Mar 2007) ISSN: 1534-7354 [Print] United States
• PMID: 17351029 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cyclooxygenase 2 Inhibitors
• Plant Extracts
• Zyflamend
• Prostate-Specific Antigen

Topics

• Aged
• Biopsy, Needle
• Cyclooxygenase 2 Inhibitors (pharmacology, therapeutic use)
• Humans
• Male
• Plant Extracts (pharmacology, therapeutic use)
• Prostate-Specific Antigen (drug effects)
• Prostatic Intraepithelial Neoplasia (drug therapy)
• Prostatic Neoplasms (prevention & control)